Skip to main content
SpringerLink
Log in

Addition of pertuzumab to trastuzumab cost effective

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. human epidermal growth factor receptor 2

  2. 2017 US dollars

Reference

  • Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value in Health : 13 Mar 2019. Available from: URL: https://doi.org/10.1016/j.jval.2018.11.014

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Addition of pertuzumab to trastuzumab cost effective. PharmacoEcon Outcomes News 824, 4 (2019). https://doi.org/10.1007/s40274-019-5732-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5732-x

Search

Navigation